Cree Bruce
Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA.
Neurologist. 2006 Jul;12(4):171-8. doi: 10.1097/01.nrl.0000204859.15501.6b.
Monoclonal antibodies constitute a relatively new class of therapeutic agent designed to interact with specific target antigens. Monoclonal antibodies can be created to deplete cell lineages or antagonize receptors for which small molecule drugs are not available. Because of their accessibility, proteins expressed on the surface of immune system cell lineages are appealing targets for monoclonal antibody therapies.
To review monoclonal antibodies currently under investigation for treatment of multiple sclerosis (MS). This was a review of the literature and ongoing clinical trials. Alemtuzumab, daclizumab, rituximab, and natalizumab are monoclonal antibodies at different stages of clinical development that show promise as MS disease modifying therapies.
Several monoclonal antibodies directed against antigens present on the cell surface of immune system cell lines are promising candidates for immune suppression therapies in MS. Because these drugs are still in development, their clinical benefits and safety profiles are not fully established. Nevertheless, it seems possible that their specificity will offer advantages over broad-spectrum immune suppressing therapies.
单克隆抗体是一类相对新型的治疗药物，旨在与特定靶抗原相互作用。可以制备单克隆抗体来清除细胞谱系或拮抗小分子药物无法作用的受体。由于免疫系统细胞谱系表面表达的蛋白质易于获取，因此它们是单克隆抗体疗法颇具吸引力的靶点。
对目前正在研究用于治疗多发性硬化症（MS）的单克隆抗体进行综述。这是一篇文献综述及正在进行的临床试验。阿仑单抗、达利珠单抗、利妥昔单抗和那他珠单抗是处于临床开发不同阶段的单克隆抗体，显示出作为MS疾病修饰疗法的前景。
几种针对免疫系统细胞系细胞表面存在的抗原的单克隆抗体是MS免疫抑制疗法颇具前景的候选药物。由于这些药物仍在研发中，它们的临床益处和安全性尚未完全确立。然而，它们的特异性似乎可能比广谱免疫抑制疗法具有优势。
